The first participant has been randomized in the PRECISE-HD Confirmatory study of Pridopidine.
Ferrer and Prilenia are pleased to update you that the first participant has been randomized in the PRECISE-HD confirmatory Phase 3 study of pridopidine, an investigational medicinal product taken as an oral capsule twice daily, in Huntington’s disease (HD).
This milestone marks the start of participant enrolment, with several US sites now active and additional sites in Canada, the EU and the UK set to follow later this year.
PRECISE-HD is designed to further evaluate the efficacy and safety of pridopidine and generate data to support regulatory evaluation. The approximately 400-participant, randomized, double-blind, placebo-controlled study will assess the effects of pridopidine on a range of clinical and functional outcomes relevant to Huntington’s disease.
Updated information on the study and open sites is available on CT/Trials: NCT07609108.
The combination of ramps, gaps, and unstable platforms makes each stage feel a little different. I usually need a couple of attempts before understanding how much acceleration is needed. Drive Mad is simple to pick up but not always easy to finish.
It's encouraging to see progress in clinical research and new studies focused on improving the lives of people affected by Huntington's disease. Research milestones like this highlight the importance of continued support, awareness, and medical advancements. In a similar way, maintaining a safe and healthy environment at home is important for overall well-being. Professional mold remediation miami fl services can help property owners address mold problems and create cleaner, healthier indoor spaces. Thank you for sharing this important update!
Really enjoyed this article. Astrology has become much more accessible with online tools that help people explore their birth information in new ways. An astrocartography chart is an interesting way to connect planetary placements with different locations around the world.
The progress of the PRECISE-HD Phase 3 study is certainly encouraging, particularly as the trial aims to enrol around 400 participants across the US, Canada, EU, and UK. Research into Huntington’s disease often takes time because of the careful processes involved in clinical trials, making the randomisation of the first participant an important step for families following developments in this area. Reading detailed trial information also reminded me of working through medical research papers at university, when finding assignment help Australia made it easier to handle lengthy and complex academic material. It will be interesting to see how quickly the international trial sites become active and what results emerge from the twice-daily oral capsule in terms of functional outcomes.
It is really encouraging to see the PRECISE-HD trial officially move forward with its first randomized participant, especially with plans to expand to around 400 people across Canada, the UK, and Europe. Navigating complex global health frameworks and international clinical trial standards always reminds me of how intricate regulation can be, almost like sorting through International Law Assignment Help Australia research topics during university. The fact that pridopidine is being tested as a simple twice-daily oral capsule makes you hope the delivery method keeps things straightforward for the individuals involved. I'll certainly be keeping an eye out for how enrolment progresses across the international sites over the coming year.